Tag: Revumenib

Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) has emerged as a leading contender among the top stocks priced under $20. On…